Top

BMC Neurology

Published in:

Open Access 01-12-2023 | Neuromyelitis Optica Spectrum Disease | Research

Integrative analysis of purine metabolites and gut microbiota in patients with neuromyelitis optica spectrum disorders after mycophenolate mofetil treatment

Authors: Gong Li, Xiaoyu Ma, Lijuan Xia, Ran Wei, Xiran Wang, Cang Li, Yuge Wang, Limin He, Hao Ren, Jian Sun, Wei Qiu

Published in: BMC Neurology | Issue 1/2023

Abstract

Background

Neuromyelitis optica spectrum disorder (NMOSD) is a recurring inflammatory demyelinating disease that is commonly observed in Asian countries like China. Prior investigations have shown that mycophenolate mofetil (MMF) with better biocompatibility compared to azathioprine (AZA), and can prevent relapses of NMOSD, but the efficacy was controversially reported in different NMOSD cases. We aimed to explore the factors that weaken efficacy of MMF in NMOSD.

Methods

A total of 34 NMOSD patients treated with MMF were prospectively enrolled and grouped according to the therapeutic efficacy as effective group (EG, n = 23) versus less-effective group (LEG, n = 11). The purine metabolites were profiled in serum samples and gut microbiota was analyzed using 16S rRNA sequencing with stool samples from the same patients.

Results

Purine salvage pathway (PSP) metabolites (inosine, hypoxanthine, xanthine, guanine and uric acid) in the serum of NMOSD patients were elevated in the LEG compared to EG (p < 0.05). Additionally, the richness and microbial diversity of gut microbiota was found to be similar between EG and LEG patients. However, LEG patients had increased presence of Clostridium and Synergistes but decreased abundance of the Coprococcus genus.

Conclusions

The PSP metabolites and composition of the gut microbiota were changed between patients with or without optimal clinical response after MMF treatment. This may help us to understand the pharmacodynamics of MMF in NMOSD.

Lucchinetti C, Guo Y, Popescu B, Fujihara K, Itoyama Y, Misu T. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol. 2014;24 1:83–97. https://doi.org/10.1111/bpa.12099.CrossRef

Mader S, Kümpfel T, Meinl E. Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated Diseases. Curr Opin Neurol. 2020;33 3:362–71. https://doi.org/10.1097/wco.0000000000000813.CrossRef

Bennett JL, Costello F, Chen JJ, Petzold A, Biousse V, Newman NJ, et al. Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. Lancet Neurol. 2023;22 1:89–100. https://doi.org/10.1016/s1474-4422(22)00187-9.CrossRef

Fu Y, Bi J, Yan Y, Sun X, Li K, Kim SY, et al. Rapid Immunodot AQP4 assay for Neuromyelitis Optica Spectrum Disorder. JAMA Neurol. 2023;80 10:1105–12. https://doi.org/10.1001/jamaneurol.2023.2974.CrossRef

Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–89. https://doi.org/10.1212/wnl.0000000000001729.CrossRefPubMedPubMedCentral

Huang Q, Wang J, Zhou Y, Yang H, Wang Z, Yan Z, et al. Low-dose mycophenolate mofetil for Treatment of Neuromyelitis Optica Spectrum Disorders: a prospective Multicenter Study in South China. Front Immunol. 2018;9:2066. https://doi.org/10.3389/fimmu.2018.02066.CrossRefPubMedPubMedCentral

Wingerchuk D, Weinshenker B. Neuromyelitis Optica. Curr Treat Options Neurol. 2008;10(1):55–66. https://doi.org/10.1007/s11940-008-0007-z.CrossRefPubMed

Yong HYF, Burton JM. A Clinical Approach to existing and emerging therapeutics in Neuromyelitis Optica Spectrum Disorder. Curr Neurol Neurosci Rep. 2023;23 9:489–506. https://doi.org/10.1007/s11910-023-01287-x.CrossRef

Allison A. Mechanisms of action of mycophenolate mofetil. Lupus. 2005;2–8. https://doi.org/10.1191/0961203305lu2109oa.

10.

Allison AC, Eugui EM. The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin Immunopathol. 1993;14 4:353–80. https://doi.org/10.1007/bf00192309.CrossRef

11.

Moreno Planas J, Cuervas-Mons Martinez V, Rubio Gonzalez E, Gomez Cruz A, Lopez-Monclus J, Sánchez-Turrion V et al. Mycophenolate mofetil can be used as monotherapy late after liver transplantation. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2004;4 10:1650–5; https://doi.org/10.1111/j.1600-6143.2004.00556.x.

12.

Heischmann S, Dzieciatkowska M, Hansen K, Leibfritz D, Christians U. The immunosuppressant mycophenolic acid alters nucleotide and lipid metabolism in an intestinal cell model. Sci Rep. 2017;7:45088. https://doi.org/10.1038/srep45088.CrossRefPubMedPubMedCentral

13.

Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, et al. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler. 2017;23 10:1377–84. https://doi.org/10.1177/1352458516678474.CrossRef

14.

Huh SY, Kim SH, Hyun JW, Joung AR, Park MS, Kim BJ, et al. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol. 2014;71 11:1372–8. https://doi.org/10.1001/jamaneurol.2014.2057.CrossRef

15.

Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009;66 9:1128–33. https://doi.org/10.1001/archneurol.2009.175.CrossRef

16.

Gong J, Qiu W, Zeng Q, Liu X, Sun X, Li H et al. Lack of short-chain fatty acids and overgrowth of opportunistic pathogens define dysbiosis of neuromyelitis optica spectrum disorders: a Chinese pilot study. Multiple sclerosis (Houndmills, Basingstoke, England). 2019;25 9:1316–25; https://doi.org/10.1177/1352458518790396.

17.

Pandit L, Cox L, Malli C, D’Cunha A, Rooney T, Lokhande H, et al. Clostridium bolteae is elevated in neuromyelitis optica spectrum disorder in India and shares sequence similarity with AQP4. Neurology(R) Neuroimmunol Neuroinflammation. 2021;8(1). https://doi.org/10.1212/nxi.0000000000000907.

18.

Cree B, Spencer C, Varrin-Doyer M, Baranzini S, Zamvil S. Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringens. Ann Neurol. 2016;80 3:443–7. https://doi.org/10.1002/ana.24718.CrossRef

19.

Wingerchuk D, Banwell B, Bennett J, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–89. https://doi.org/10.1212/wnl.0000000000001729.CrossRefPubMedPubMedCentral

20.

Benard-Seguin E, Costello F. Optic neuritis: current challenges in diagnosis and management. Curr Opin Neurol. 2023;36 1:10–8. https://doi.org/10.1097/wco.0000000000001128.CrossRef

21.

Lu JJ, Jia BJ, Yang L, Zhang W, Dong X, Li P, et al. Ultra-high performance liquid chromatography with ultraviolet and tandem mass spectrometry for simultaneous determination of metabolites in purine pathway of rat plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1036–1037:84–92. https://doi.org/10.1016/j.jchromb.2016.09.023.CrossRefPubMed

22.

Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261(1):1–16. https://doi.org/10.1007/s00415-013-7169-7.CrossRefPubMed

23.

Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010;17 8:1019–32. https://doi.org/10.1111/j.1468-1331.2010.03066.x.CrossRef

24.

Kimbrough DJ, Fujihara K, Jacob A, Lana-Peixoto MA, Leite MI, Levy M, et al. Treatment of Neuromyelitis Optica: review and recommendations. Mult Scler Relat Disord. 2012;1 4:180–7. https://doi.org/10.1016/j.msard.2012.06.002.CrossRef

25.

Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6 9:805 – 15; doi: 10.1016/s1474-4422(07)70216-8.

26.

Carnero Contentti E, Correale J. Association between Infections, the microbiome, vaccination, and neuromyelitis optica spectrum disorder. Mult Scler. 2023;29(4–5):492–501. https://doi.org/10.1177/13524585221113272.CrossRefPubMed

27.

Cui C, Ruan Y, Qiu W. Potential role of the gut microbiota in neuromyelitis optica spectrum disorder: implication for intervention. J Clin Neuroscience: Official J Neurosurgical Soc Australasia 2020;82 Pt B:193–9; https://doi.org/10.1016/j.jocn.2020.11.011.

28.

Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant. J Clin Pharm Ther. 2006;31 1:27–34. https://doi.org/10.1111/j.1365-2710.2006.00713.x.CrossRef

29.

Pillans PI, Rigby RJ, Kubler P, Willis C, Salm P, Tett SE, et al. A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients. Clin Biochem. 2001;34 1:77–81. https://doi.org/10.1016/s0009-9120(00)00196-x.CrossRef

30.

Emmanuel N, Ragunathan S, Shan Q, Wang F, Giannakou A, Huser N, et al. Purine nucleotide availability regulates mTORC1 activity through the Rheb GTPase. Cell Rep. 2017;19 13:2665–80. https://doi.org/10.1016/j.celrep.2017.05.043.CrossRef

31.

Lazzarino G, Amorini A, Petzold A, Gasperini C, Ruggieri S, Quartuccio M, et al. Serum compounds of Energy Metabolism Impairment are related to disability, Disease Course and Neuroimaging in multiple sclerosis. Mol Neurobiol. 2017;54 9:7520–33. https://doi.org/10.1007/s12035-016-0257-9.CrossRef

32.

Kuračka L, Kalnovičová T, Kucharská J, Turčáni P. Multiple sclerosis: evaluation of purine nucleotide metabolism in central nervous system in association with serum levels of selected fat-soluble antioxidants. Multiple Scler Int. 2014;2014:759808. https://doi.org/10.1155/2014/759808.CrossRef

33.

Shu Y, Li H, Zhang L, Wang Y, Long Y, Li R, et al. Elevated cerebrospinal fluid uric acid during relapse of neuromyelitis optica spectrum disorders. Brain and Behavior. 2017;7(1):e00584. https://doi.org/10.1002/brb3.584.CrossRefPubMed

34.

Wei Y, Wu D, Chen Y, Dong C, Qi J, Wu Y, et al. Population pharmacokinetics of mycophenolate mofetil in pediatric patients early after liver transplantation. Front Pharmacol. 2022;13:1002628. https://doi.org/10.3389/fphar.2022.1002628.CrossRefPubMedPubMedCentral

35.

Taylor M, Flannigan K, Rahim H, Mohamud A, Lewis I, Hirota S, et al. Vancomycin relieves mycophenolate mofetil-induced gastrointestinal toxicity by eliminating gut bacterial β-glucuronidase activity. Sci Adv. 2019;5 8:eaax2358. https://doi.org/10.1126/sciadv.aax2358.CrossRef

36.

Simpson JB, Sekela JJ, Graboski AL, Borlandelli VB, Bivins MM, Barker NK, et al. Metagenomics combined with activity-based proteomics point to gut bacterial enzymes that reactivate mycophenolate. Gut Microbes. 2022;14(1:2107289). https://doi.org/10.1080/19490976.2022.2107289.

37.

Khan MH, Onyeaghala GC, Rashidi A, Holtan SG, Khoruts A, Israni A, et al. Fecal β-glucuronidase activity differs between hematopoietic cell and kidney transplantation and a possible mechanism for disparate dose requirements. Gut Microbes. 2022;14(1:2108279). https://doi.org/10.1080/19490976.2022.2108279.

38.

Cree BA, Spencer CM, Varrin-Doyer M, Baranzini SE, Zamvil SS. Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringens. Ann Neurol. 2016;80 3:443–7. https://doi.org/10.1002/ana.24718.CrossRef

39.

Gong J, Qiu W, Zeng Q, Liu X, Sun X, Li H, et al. Lack of short-chain fatty acids and overgrowth of opportunistic pathogens define dysbiosis of neuromyelitis optica spectrum disorders: a Chinese pilot study. Mult Scler. 2019;25 9:1316–25. https://doi.org/10.1177/1352458518790396.CrossRef

40.

Liu C, Du P, Cheng Y, Guo Y, Hu B, Yao W, et al. Study on fecal fermentation characteristics of aloe polysaccharides in vitro and their predictive modeling. Carbohydr Polym. 2021;256:117571. https://doi.org/10.1016/j.carbpol.2020.117571.CrossRefPubMed

41.

Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, et al. Extensive impact of non-antibiotic Drugs on human gut bacteria. Nature. 2018;555 7698:623–8. https://doi.org/10.1038/nature25979.CrossRef

42.

Nikolova VL, Smith MRB, Hall LJ, Cleare AJ, Stone JM, Young AH. Perturbations in Gut Microbiota Composition in Psychiatric disorders: a review and Meta-analysis. JAMA Psychiatry. 2021;78 12:1343–54. https://doi.org/10.1001/jamapsychiatry.2021.2573.CrossRef

43.

Huang S, Mao J, Zhou L, Xiong X, Deng Y. The imbalance of gut microbiota and its correlation with plasma inflammatory cytokines in pemphigus vulgaris patients. Scand J Immunol. 2019;90 3:e12799. https://doi.org/10.1111/sji.12799.CrossRef

44.

Yeh N, Hsu C, Tsai T, Chiu H. Gut Microbiome in Psoriasis is perturbed differently during secukinumab and Ustekinumab Therapy and Associated with response to treatment. Clin Drug Investig. 2019;39 12:1195–203. https://doi.org/10.1007/s40261-019-00849-7.CrossRef

45.

Shi Z, Qiu Y, Wang J, Fang Y, Zhang Y, Chen H, et al. Dysbiosis of gut microbiota in patients with neuromyelitis optica spectrum disorders: a cross sectional study. J Neuroimmunol. 2020;339:577126. https://doi.org/10.1016/j.jneuroim.2019.577126.CrossRefPubMed

Title: Integrative analysis of purine metabolites and gut microbiota in patients with neuromyelitis optica spectrum disorders after mycophenolate mofetil treatment
Authors: Gong Li
Xiaoyu Ma
Lijuan Xia
Ran Wei
Xiran Wang
Cang Li
Yuge Wang
Limin He
Hao Ren
Jian Sun
Wei Qiu
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Neuromyelitis Optica Spectrum Disease
Mycophenolate Mofetil
Respiratory Microbiota
Clostridium
Xanthine Alkaloid
Azathioprine
Azathioprine
Published in: BMC Neurology / Issue 1/2023
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-023-03500-3

2024 ASCO Annual Meeting

Springer Medicine

Integrative analysis of purine metabolites and gut microbiota in patients with neuromyelitis optica spectrum disorders after mycophenolate mofetil treatment

Abstract

Background

Methods

Results

Conclusions

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Neutral lipid storage disease with myopathy and myotonia associated to pathogenic variants on PNPLA2 and CLCN1 genes: case report

Multimodal agility-based exercise training (MAT) versus strength and endurance training (SET) to improve multiple sclerosis-related fatigue and fatigability during inpatient rehabilitation: a randomized controlled pilot and feasibility study [ReFEx]

Association of gut microbiome with risk of intracranial aneurysm: a mendelian randomization study

Cycling in primary progressive multiple sclerosis (CYPRO): study protocol for a randomized controlled superiority trial evaluating the effects of high-intensity interval training in persons with primary progressive multiple sclerosis

Serum LDH levels may predict poor neurological outcome after aneurysmal subarachnoid hemorrhage

Subarachnoid extension and unfavorable outcomes in patients with supratentorial intracerebral hemorrhage